345 related articles for article (PubMed ID: 19075018)
21. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
22. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
25. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain.
Johnson MD; Vito F; Xu H
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):250-3. PubMed ID: 20090516
[TBL] [Abstract][Full Text] [Related]
26. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
27. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
28. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
Xiang X; Feng M; Felder M; Connor JP; Man YG; Patankar MS; Ho M
J Cancer; 2011; 2():280-91. PubMed ID: 21611109
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
30. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
33. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
34. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
[TBL] [Abstract][Full Text] [Related]
35. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
36. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
37. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
39. Correlation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis.
Wang L; Wang X; Sun N; Chen B
Scand J Clin Lab Invest; 2023 Apr; 83(2):74-78. PubMed ID: 36705231
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
